Where does Elanco US Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Elanco US Inc. ranks #8,018 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Elanco US Inc. hold?

Elanco US Inc. holds 40 US utility patents granted between 2018 and 2025, spanning 12 technology areas.

What is Elanco US Inc.'s Innovation Score?

Elanco US Inc. has an Innovation Score of 46.2 out of 100 (top 21% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Elanco US Inc. focus on?

Elanco US Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 33 patents, ranking #585 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Elanco US Inc.'s patent grant rate increasing or decreasing?

Elanco US Inc.'s recent grant velocity is +67% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Elanco US Inc.'s patents?

Elanco US Inc.'s patents average 15.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Elanco US Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Elanco US Inc.

USPTO PatentsView assignee record - 40 granted patents across 12 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Elanco ranks #8,018 of 49,997 tracked US assignees by granted-patent volume, with 40 patents across 12 technology areas.

#8,018
of 49,997 US assignees by volume: Top 21%
by Innovation Score (46.2/100): 15.4
avg claims per patent: +67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8018 · US Corporation #8,018 · 40 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 40 grants
UPPER-Q #8,018/49,997
PHOTO-FINISH Eagle View
CPC-FOCUS A61P · 12 areas
INNOV-PAR 46.2/100
CLAIMS-RICH 15.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eagle View Technologies, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Elanco’s 46.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.8 pts (28%) Velocity 11.9 pts (26%) Breadth 12.2 pts (26%) Claim depth 9.2 pts (20%)

Qualcomm Incorporated · highest

85
ATEME · near

46
Elanco US · this assignee

46
Flow Control · near

46
Guangdong Aoyun… · near

46
OP Solutions · near

46
3D Lighting… · lowest

7

What this shows Elanco's Innovation Score is 46.2/100 (top 21% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Elanco?

Each dot is one of Elanco’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Elanco’s own 15.4 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Elanco vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Elanco's grants concentrate

Elanco US Inc. is a focused PatentsView assignee: 12 CPC subclasses with 82.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (7 grants) versus a trough of 1 in 2020. By volume, Elanco sits between Endoevolution, LLC and Foreo Inc..

Elanco's three-year grant acceleration

Elanco US Inc. shows 16 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Endoevolution

40
ERP Power

40
Eagle View

40
Eagleburgmann Ger…

40
Endogastric Solut…

40
Eyeverify

40
Findlay Machine &…

40
Foreo

40
Elanco US ◀

40

What this shows Elanco holds 40 patents at rank #8,021, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Elanco

By rank, the assignees closest to #8,021 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Elanco's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Elanco, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Elanco ranks #585 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Flow Control LLC 46 ATEME 46 OP Solutions, LLC 46 Guangdong Aoyun Technology Co., Ltd. 46

Elanco's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Elanco US Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	7	17.5%
2019	5	12.5%
2020	1	2.5%
2021	3	7.5%
2022	5	12.5%
2023	6	15.0%
2024	5	12.5%
2025partial year	8	20.0%

Which technologies does Elanco US Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 33

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 31

C07K - Peptides 15

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

A23K - Fodder 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 4

C07D - Heterocyclic Compounds 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C12Y - Enzymes 2

A61D - Veterinary Instruments, Implements, Tools, OR Methods 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Elanco US Inc.'s patent record in context - here's where to go next.

Elanco US Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 82.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,018 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Elanco US Inc. against Endoevolution, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.